To determine whether CD58 silencing exerts an antitumor effect via the inhibition of the AKT/GSK-3/-Catenin pathway, CD58 knockdown HCC cells were treated with Akt activator (SC-79) and AKT inhibitor (LY294002). The gene discussed is AKT1; the disease is hepatocellular carcinoma.